BPCR Stock Overview
An investment trust, primarily invests in interest-bearing debt assets. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
BioPharma Credit PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.85 |
| 52 Week High | US$0.94 |
| 52 Week Low | US$0.83 |
| Beta | 0.23 |
| 1 Month Change | -2.97% |
| 3 Month Change | -6.18% |
| 1 Year Change | -4.06% |
| 3 Year Change | -12.19% |
| 5 Year Change | -16.67% |
| Change since IPO | -17.68% |
Recent News & Updates
Shareholder Returns
| BPCR | GB Capital Markets | GB Market | |
|---|---|---|---|
| 7D | -1.6% | -1.2% | -2.6% |
| 1Y | -4.1% | 19.7% | 2.7% |
Return vs Industry: BPCR underperformed the UK Capital Markets industry which returned 19.7% over the past year.
Return vs Market: BPCR underperformed the UK Market which returned 2.7% over the past year.
Price Volatility
| BPCR volatility | |
|---|---|
| BPCR Average Weekly Movement | 2.2% |
| Capital Markets Industry Average Movement | 3.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: BPCR has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: BPCR's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | n/a | www.bpcruk.com |
BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. Its debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. BioPharma Credit PLC was incorporated in 2016 and is based in London, the United Kingdom.
BioPharma Credit PLC Fundamentals Summary
| BPCR fundamental statistics | |
|---|---|
| Market cap | US$1.01b |
| Earnings (TTM) | US$109.36m |
| Revenue (TTM) | US$136.37m |
9.2x
P/E Ratio7.4x
P/S RatioIs BPCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BPCR income statement (TTM) | |
|---|---|
| Revenue | US$136.37m |
| Cost of Revenue | US$0 |
| Gross Profit | US$136.37m |
| Other Expenses | US$27.01m |
| Earnings | US$109.36m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.092 |
| Gross Margin | 100.00% |
| Net Profit Margin | 80.20% |
| Debt/Equity Ratio | 0% |
How did BPCR perform over the long term?
See historical performance and comparisonDividends
11.5%
Current Dividend Yield82%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 23:52 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BioPharma Credit PLC is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Hose | Jefferies LLC |
| Sachin Saggar | Stifel, Equities Research |